Editas Medicine, Inc. (EDIT, Financial), a company focused on genome editing technologies, experienced a significant stock drop of 5.09%, with shares priced at $2.96. The trading volume reached 1.28 million shares, resulting in a turnover rate of 1.56% and a price fluctuation of 4.49%.
Recent financial disclosures reveal that Editas Medicine, Inc. reported revenue of $513,000, a net loss of $67.61 million, and earnings per share of -$0.82. The company's gross profit was negative at $907,000, with a price-to-earnings ratio of -1.27.
Analysts remain divided on the stock. Out of 19 firms covering the stock, 53% recommend buying, while 47% suggest holding. Notably, no firm advises selling.
In the biotech sector where Editas operates, the industry saw a modest increase of 0.42%. Other stocks showing notable performance include Seastar Medical Holding Corp, Nls Pharmaceutics Ltd, and Pasithea Therapeutics Corp, with significant gains. Meanwhile, companies like Aditxt, Inc. and Tempest Therapeutics, Inc. also showed high activity with turnover rates of 418.30% and 186.04% respectively.
Editas Medicine, Inc. is at the forefront of developing transformative genomic medicines, focusing on CRISPR/Cas9 technology. This tech utilizes a protein-RNA complex designed to target and repair specific DNA sequences.
